Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AR-42 with Pomalidomide in Relapsed Multiple Myeloma
NCT02569320Phase 1Completed
- Sponsor
- The Ohio State University Comprehensive Cancer Center – James Cancer Hospital
- Start
- May 2016
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of AR-42 in multiple myeloma (MM), sponsored by The Ohio State University Comprehensive Cancer Center – James Cancer Hospital. Primary endpoint: Maximum Tolerated Dose at 21 days. Started May 2016; status: completed.
02
Drugs
AR-42
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02569320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02569320.